Payment overview · 2025
General Payments
$665.68
37 reported records · 11 companies
Healthcare provider profile · identity verified
Brent E Holt, MD
Allopathic & Osteopathic Physicians|Family Medicine · POCAHONTAS, AR · NPI 1053300558
Verified facts
What the public records show
CMS Open Payments records show Brent E Holt, MD received $665.68 in general payments during 2025 across 37 reported records.
AstraZeneca Pharmaceuticals LP accounted for 28.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Gemtesa, Nurtec Odt, Ozempic, Rexulti.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Vraylar by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 121 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 131 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Nurtec Odt by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $190.88 | 28.7% | 6 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $141.18 | 21.2% | 11 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $68.52 | 10.3% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $63.76 | 9.6% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $57.39 | 8.6% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $32.60 | 4.9% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $31.42 | 4.7% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $30.28 | 4.5% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $19.00 | 2.9% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $16.64 | 2.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.01 | 2.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $665.68 | 37 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $153.79 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $132.75 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $126.91 | 10 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $126.22 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $112.61 | 9 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $68.52 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $68.52 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $63.76 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $57.39 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $32.60 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $31.42 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $19.00 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $16.64 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $16.64 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $15.94 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.34 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $14.27 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $14.01 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.01 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 131 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 121 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 84 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
56 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
121 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
84 | 18 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
131 | 27 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 585 | 135 |
| Amlodipine Besylate | Amlodipine Besylate | 573 | 126 |
| Pantoprazole Sodium | Pantoprazole Sodium | 570 | 125 |
| Levothyroxine Sodium | Levothyroxine Sodium | 472 | 86 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 465 | 91 |
| Losartan Potassium | Losartan Potassium | 415 | 92 |
| Gabapentin | Gabapentin | 389 | 77 |
| Furosemide | Furosemide | 312 | 67 |
| Montelukast Sodium | Montelukast Sodium | 306 | 67 |
| Lisinopril | Lisinopril | 287 | 65 |
| Sertraline Hcl | Sertraline Hcl | 281 | 54 |
| Trazodone Hcl | Trazodone Hcl | 273 | 58 |
| Potassium Chloride | Potassium Chloride | 253 | 51 |
| Carvedilol | Carvedilol | 230 | 44 |
| Jardiance | Empagliflozin | 229 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 219 | 46 |
| Hydrochlorothiazide | Hydrochlorothiazide | 217 | 49 |
| Metformin Hcl | Metformin Hcl | 214 | 51 |
| Meloxicam | Meloxicam | 206 | 52 |
| Metoprolol Tartrate | Metoprolol Tartrate | 193 | 36 |
| Omeprazole | Omeprazole | 181 | 44 |
| Clopidogrel | Clopidogrel Bisulfate | 176 | 34 |
| Citalopram Hbr | Citalopram Hydrobromide | 172 | 32 |
| Celecoxib | Celecoxib | 171 | 35 |
| Tamsulosin Hcl | Tamsulosin Hcl | 161 | 39 |
| Fluticasone Propionate | Fluticasone Propionate | 160 | 46 |
| Donepezil Hcl | Donepezil Hcl | 158 | 35 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 152 | 29 |
| Duloxetine Hcl | Duloxetine Hcl | 146 | 32 |
| Eliquis | Apixaban | 131 | 27 |
| Spironolactone | Spironolactone | 125 | 24 |
| Farxiga | Dapagliflozin Propanediol | 121 | 15 |
| Allopurinol | Allopurinol | 120 | 25 |
| Metoprolol Succinate | Metoprolol Succinate | 119 | 28 |
| Bupropion Xl | Bupropion Hcl | 115 | 25 |
| Tresiba Flextouch U-100 | Insulin Degludec | 107 | 20 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 103 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 98 | 20 |
| Pregabalin | Pregabalin | 97 | 23 |
| Myrbetriq | Mirabegron | 95 | 13 |
| Warfarin Sodium | Warfarin Sodium | 92 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 91 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 89 | 20 |
| Tizanidine Hcl | Tizanidine Hcl | 89 | 38 |
| Fluoxetine Hcl | Fluoxetine Hcl | 88 | 21 |
| Januvia | Sitagliptin Phosphate | 88 | 11 |
| Ozempic | Semaglutide | 84 | 18 |
| Buspirone Hcl | Buspirone Hcl | 83 | 20 |
| Mirtazapine | Mirtazapine | 79 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 78 | 36 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 76 | 37 |
| Ezetimibe | Ezetimibe | 74 | 20 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 74 | 13 |
| Clonazepam | Clonazepam | 71 | 13 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 71 | 65 |
| Amitriptyline Hcl | Amitriptyline Hcl | 68 | 13 |
| Prednisone | Prednisone | 68 | 46 |
| Memantine Hcl | Memantine Hcl | 66 | 12 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 63 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 63 | 13 |
| Propranolol Hcl | Propranolol Hcl | 62 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 62 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 60 | 13 |
| Xarelto | Rivaroxaban | 60 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 57 | 15 |
| Linzess | Linaclotide | 56 | suppressed |
| Simvastatin | Simvastatin | 56 | 14 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 54 | 14 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 53 | 16 |
| Lamotrigine | Lamotrigine | 53 | suppressed |
| Primidone | Primidone | 52 | 13 |
| Atenolol | Atenolol | 51 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 49 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 47 | suppressed |
| Mounjaro | Tirzepatide | 46 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 46 | suppressed |
| Famotidine | Famotidine | 45 | 14 |
| Metformin Hcl Er | Metformin Hcl | 45 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 45 | 18 |
| Glipizide Er | Glipizide | 44 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 44 | 13 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 43 | 12 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 43 | suppressed |
| Valsartan | Valsartan | 42 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 40 | suppressed |
| Azithromycin | Azithromycin | 39 | 36 |
| Trulicity | Dulaglutide | 39 | suppressed |
| Tradjenta | Linagliptin | 37 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 36 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 35 | suppressed |
| Estradiol | Estradiol | 35 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 35 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Synthroid | Levothyroxine Sodium | 34 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 34 | suppressed |
| Chlorthalidone | Chlorthalidone | 33 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 33 | 13 |
| Nystatin | Nystatin | 33 | 20 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 33 | suppressed |
| Fluconazole | Fluconazole | 31 | 24 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 31 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 31 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 30 | 23 |
| Ventolin Hfa | Albuterol Sulfate | 30 | 12 |
| Aripiprazole | Aripiprazole | 29 | suppressed |
| Baclofen | Baclofen | 29 | suppressed |
| Sotalol | Sotalol Hcl | 29 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 29 | 19 |
| Breo Ellipta | Fluticasone/Vilanterol | 28 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 28 | 25 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 28 | suppressed |
| Topiramate | Topiramate | 28 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 27 | suppressed |
| Finasteride | Finasteride | 27 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 27 | suppressed |
| Alprazolam | Alprazolam | 26 | 11 |
| Azelastine Hcl | Azelastine Hcl | 26 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 26 | suppressed |
| Calcitriol | Calcitriol | 26 | suppressed |
| Vraylar | Cariprazine Hcl | 26 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 25 | suppressed |
| Fenofibrate | Fenofibrate | 25 | suppressed |
| Levetiracetam | Levetiracetam | 25 | suppressed |
| Nitroglycerin | Nitroglycerin | 25 | 20 |
| Ropinirole Hcl | Ropinirole Hcl | 25 | suppressed |
| Sod Sulf-Potass Sulf-Mag Sulf | Sodium, Potassium,mag Sulfates | 24 | 23 |
| Bumetanide | Bumetanide | 23 | suppressed |
| Cephalexin | Cephalexin | 23 | 16 |
| Lovastatin | Lovastatin | 22 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 22 | suppressed |
| Mupirocin | Mupirocin | 22 | 17 |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 22 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Amoxicillin | Amoxicillin | 21 | 16 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 21 | suppressed |
| Cefdinir | Cefdinir | 21 | 18 |
| Entresto | Sacubitril/Valsartan | 21 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 21 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Lansoprazole | Lansoprazole | 20 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 19 | 15 |
| Glipizide | Glipizide | 19 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 19 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 18 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 17 | suppressed |
| Diazepam | Diazepam | 17 | suppressed |
| Nabumetone | Nabumetone | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 17 | 16 |
| Raloxifene Hcl | Raloxifene Hcl | 17 | suppressed |
| Ramipril | Ramipril | 17 | suppressed |
| Ranolazine Er | Ranolazine | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Digoxin | Digoxin | 16 | suppressed |
| Febuxostat | Febuxostat | 16 | suppressed |
| Praluent Pen | Alirocumab | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | 12 |
| Nurtec Odt | Rimegepant Sulfate | 15 | suppressed |
| Anastrozole | Anastrozole | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Gemtesa | Vibegron | 14 | suppressed |
| Norethindron-Ethinyl Estradiol | Norethindrone Ac/Eth Estradiol | 14 | suppressed |
| Rexulti | Brexpiprazole | 14 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Latanoprost | Latanoprost | 13 | suppressed |
| Lubiprostone | Lubiprostone | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Repatha Sureclick | Evolocumab | 13 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 11 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Moxifloxacin | Moxifloxacin Hcl | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Prolia | Denosumab | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $665.68 · 37 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, CAPLYTA, Cologuard Collection Kit, ELIQUIS, EVENITY, FARXIGA, GEMTESA, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, XIFAXAN | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error